Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Opinion
  • Published:

Why does the treatment of anaemia not improve cardiac outcomes in CKD?

Nature Reviews Nephrology volume 9, pages 59–61 (2013)Cite this article

Subjects

Abstract

Anaemia is an independent predictor of adverse outcomes in chronic kidney disease (CKD). Randomized trials using erythropoiesis-stimulating agents (ESAs) in patients with severe anaemia (baseline haemoglobin level <100 g/l) have been small, and the hypothesis that partial correction of severe anaemia may prevent cardiovascular events is tenable but unproven. Results from randomized trials of moderate anaemia correction with ESAs do not support the hypothesis that moderate anaemia is a cardiovascular risk factor. This Perspectives article discusses the idea that this finding may have been a result of the inadequate design of trials, co-intervention with high doses of ESAs or intravenous iron hiding a beneficial effect. Another idea is also discussed—that moderate anaemia is a marker of the degree of renal impairment and that its association with cardiovascular disease merely signifies that other factors are present that are pathogenic to the heart and associated with both kidney impairment and anaemia.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Shamseddin, M. K. & Parfrey, P. S. Mechanisms of the cardiorenal syndromes. Nat. Rev. Nephrol. 5, 641–649 (2009).

    Article  Google Scholar 

  2. Foley, R. N. et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am. J. Kidney Dis. 28, 53–61 (1996).

    Article  CAS  Google Scholar 

  3. Ofsthun, N., Labrecque, J., Lacson, E., Keen, M. & Lazarus, J. M. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int. 63, 1908–1914 (2003).

    Article  Google Scholar 

  4. Regidor, D. L. et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J. Am. Soc. Nephrol. 16, 1181–1191 (2006).

    Article  Google Scholar 

  5. Rigatto, C. et al. Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. J. Am. Soc. Nephrol. 13, 1084–1090 (2002).

    PubMed  Google Scholar 

  6. Rigatto, C. et al. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic valve and impact of blood pressure and anemia. J. Am. Soc. Nephrol. 14, 462–468 (2003).

    Article  Google Scholar 

  7. Besarab, A. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 339, 584–590 (1998).

    Article  CAS  Google Scholar 

  8. Parfrey, P. S. et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J. Am. Soc. Nephrol. 16, 2180–2189 (2005).

    Article  Google Scholar 

  9. Drüeke, T. B. et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 355, 2071–2084 (2006).

    Article  Google Scholar 

  10. Singh, A. K. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355, 2085–2098 (2006).

    Article  CAS  Google Scholar 

  11. Pfeffer, M. A. et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361, 2019–2032 (2009).

    Article  Google Scholar 

  12. Parfrey, P. S., Lauve, M., Latremonille-Vian, D. & Lefebvre, P. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. Clin. J. Am. Soc. Nephrol. 4, 755–762 (2009).

    Article  CAS  Google Scholar 

  13. Kidney Disease: Improving Global outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. Suppl. 2, 279–335 (2012).

  14. Foley, R. N., Curtis, B. M., Randell, E. W. & Parfrey, P. S. Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clin. J. Am. Soc. Nephrol. 5, 805–813 (2010).

    Article  CAS  Google Scholar 

  15. Eckardt, K. U. et al. Left ventricular geometry predicts cardiovascular outcome associated with anemia correction in CKD. J. Am. Soc. Nephrol. 20, 2651–2660 (2009).

    Article  CAS  Google Scholar 

  16. Solomon, S. D. et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N. Engl. J. Med. 363, 1146–1155 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, The Health Sciences Centre, Memorial University, St John's, A1B 3V6, NL, Canada

    Patrick S. Parfrey

Authors
  1. Patrick S. Parfrey
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

P. S. Parfrey declares an association with Amgen (consultant, sponsored to give invited talks at hospitals).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parfrey, P. Why does the treatment of anaemia not improve cardiac outcomes in CKD?. Nat Rev Nephrol 9, 59–61 (2013). https://doi.org/10.1038/nrneph.2012.239

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2012.239

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing